This post should be pinned or stickied! great work Pete!
Go Leo & IPIX!
_____________________________________________________________________________________________________________________
to clarify my prior post that said the peer review article should change things in a hurry, I realized I needed to support that statement so here goes:
The peer review article should change that in a hurry.
Why?
IPIX hasn't had the funds to run a thorough test of Brilacidin with a verifiable third party doing the testing for the medical world to realize the advantages of this foundational drug of a new arm of medicine and this has led to IPIX not being able to reach a large mass of medical researchers because they do not recognize biotech startup PRs (which is all IPIX has had up to this point in time).
The CV19 was a blessing for IPIX, Brilacidin, and in the end will prove to have been a blessing for the world in the sense that it allowed this new class of medicine, defensin mimetics, and specifically Briacidin, the foundational cornerstone of the mimetics, to become familiar across the world of medicine.
People bitch that IPIX couldn't find partners, well with the above restraints the only people that knew about Brilacidin were obviously trying to get it on the cheap, either by driving IPIX into bankruptcy or partnering with IPIX for a mere penny on the dollar or so.
But just as a volcano needs all the parameters to come together at just the right time for a major eruption, so too did Brilacidin and IPIX. I predict the pre peer review article publication, due any day now, will be the final catalyst to allow Brilacidin to become a medical 'Krakatoa', and will explode across the world of medicine just as Krakatoa exploded across the news of the world.
The pre review article will lead to the IND acceptance, grant money, and a human trial announcement in a VERY VERY SHORT TIME to further increase the size of the Brilacidin explosion.
Best wishes to all longs over the next two weeks!!!
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to
